EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Christoffer Trier Maansson iD, Anders Lade Nielsen, Boe Sandahl Sorensen iD

Molecular Oncology · 2026

DOI: 10.1002/1878-0261.70145 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Oncology, 2026. Verfasst von Christoffer Trier Maansson und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Aarhus University Hospital, Denmark. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Cell-Free Nucleic Acids, Neoplasms, Circulating Tumor DNA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 171 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kræftens Bekæmpelse, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liquid biopsies containing circulating tumor DNA (ctDNA) are important biomarkers across several forms of cancer. The detection of mutations in cell‐free DNA (cfDNA) indicates the presence of ctDNA. However, unsatisfactory ctDNA mutation sensitivities, issues with sequencing errors, and clonal hematopoiesis variants have limited the clinical utility of mutation‐based ctDNA assays. Recently, a new avenue of cfDNA assays has been developed, focusing on cfDNA epigenetics. Here, we outline the recent advancements in cfDNA epigenetics, focusing on cfDNA methylation, fragmentomics, and post‐translational modifications (PTMs) of circulating nucleosomes. We present various methylation strategies concerning ctDNA detection and tissue of origin (TOO) analyses. cfDNA fragmentomics focuses on cfDNA fragment lengths, fragment end motifs, and nucleosome positioning to infer gene expression and estimate the ctDNA fraction. Lastly, we discuss the development of cell‐free chromatin immunoprecipitation of circulating nucleosomes with PTMs. This method has been implemented to detect tumor gene expression, TOO, and treatment resistance. Combining the epigenetic features of cfDNA will expand the utility of liquid biopsies to give a more comprehensive insight into tumor biology, treatment response, and resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epigenesis, GeneticCell-Free Nucleic AcidsNeoplasmsCirculating Tumor DNAHumansLiquid BiopsyNucleosomesBiomarkers, TumorDNA MethylationProtein Processing, Post-Translational

Stichwörter der Autor:innen

cell‐free ChIPcell‐free DNAepigeneticsfragmentomicsliquid biopsymethylation

Substanzen

Cell-Free Nucleic AcidsNucleosomesCirculating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Clinical Biochemistry, Aarhus University Hospital, Denmark.
  • Department of Clinical Medicine, Aarhus University, Denmark.
  • Department of Biomedicine, Aarhus University, Denmark.

ORCID-Profile: Christoffer Trier Maansson, Boe Sandahl Sorensen

Förderung

  • Kræftens Bekæmpelse
  • Novo Nordisk Fonden

Zitieren

APA

Maansson, C. T., Nielsen, A. L., & Sorensen, B. S. (2026). Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA. Molecular Oncology. https://doi.org/10.1002/1878-0261.70145

Vancouver

Maansson CT, Nielsen AL, Sorensen BS. Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA. Molecular Oncology. 2026. doi:10.1002/1878-0261.70145

BibTeX
@article{Maansson2026,
  author = {Maansson, Christoffer Trier and Nielsen, Anders Lade and Sorensen, Boe Sandahl},
  title = {Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA},
  journal = {Molecular Oncology},
  year = {2026},
  doi = {10.1002/1878-0261.70145}
}
Kostenlos starten →